Seeking Alpha

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality ...
The American Journal of Managed Care

Association of Wound Healing With Quality and Continuity of Care and Sociodemographic Characteristics

Based on the analysis of electronic health records from 480 clinics, we found that better care quality and continuity are associated with better-than-expected wound healing performance. Objectives: To ...
Healio

Topical gel improves odor, reduces pain for complex, cancer-related wounds

Please provide your email address to receive an email when new articles are posted on . VT-1953, a first-in-class topical immunomodulator, improved malodor associated with malignant fungating wounds ...
ascopubs.org

Maggot Debridement Therapy of a Leg Wound From Kaposi's Sarcoma: A Case Report

Malodorous, fungating wounds in the final stages of life for a patient with cancer have remained a challenge to physicians and wound care nurses as a result of the incurable nature of the disease and ...
WATE 6 On Your Side

Vyome Therapeutics Presents Positive Data from Early Analysis of a Phase 2 Study of VT-1953 in Malignant Fungating Wound

CAMBRIDGE, MA, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- • VT-1953 treatment reduces malignant fungating wound-associated malodor over a 14 day period ...